KRONOS BIO INC. - COM

Kronos Bio and Tempus Announce Multi-Year Collaboration to Provide Kronos Bio With Access to Tempus’ Platform

08 Nov 2021 16:44:44 By Nasdaq GlobeNewswire

Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Poster Presentation at AACR-NCI-EORTC 2021

30 Sep 2021 16:35:57 By Nasdaq GlobeNewswire

Kronos Bio Appoints Marni Kottle as Senior Vice President of Corporate Communications and Investor Relations

14 Sep 2021 08:00:02 By Nasdaq GlobeNewswire

Kronos Bio Announces Participation in H.C. Wainwright 23rd Annual Global Investment Conference 

07 Sep 2021 07:00:01 By Nasdaq GlobeNewswire

Kronos Bio Reports Recent Business Progress and Second Quarter Financial Results

12 Aug 2021 16:05:01 By Nasdaq GlobeNewswire

Kronos Bio Announces FDA Clearance of Investigational New Drug Application for Lanraplenib (LANRA) for Treatment of Patients with Acute Myeloid Leukemia (AML)

27 Jul 2021 08:00:05 By Nasdaq GlobeNewswire

Kronos Bio to Highlight Progress Across Pipeline and Outline Growth Strategy at Virtual R&D Day Today

25 May 2021 08:00:03 By Nasdaq GlobeNewswire

Kronos Bio Reports Recent Business Progress and First Quarter Financial Results and Announces Virtual R&D Day

11 May 2021 16:05:01 By Nasdaq GlobeNewswire

Kronos Bio Announces Participation in Bank of America Securities 2021 Health Care Conference

06 May 2021 08:00:02 By Nasdaq GlobeNewswire

Kronos Bio Presents Preclinical Data for Oral CDK9 Inhibitor KB-0742 Demonstrating Sustained Inhibition of Tumor Growth in Multiple Cancers at AACR Annual Meeting 2021

10 Apr 2021 08:30:00 By Nasdaq GlobeNewswire

Kronos Bio Comments on the Passing of Board Member John C. Martin, Ph.D.

31 Mar 2021 11:25:04 By Nasdaq GlobeNewswire

Kronos Bio Appoints Taiyin Yang, Ph.D., to Board of Directors

26 Mar 2021 08:00:00 By Nasdaq GlobeNewswire

Kronos Bio Reports Recent Business Progress and Fourth Quarter and Full Year 2020 Financial Results

23 Mar 2021 16:05:00 By Nasdaq GlobeNewswire

Kronos Bio to Present Pre-Clinical Data at the AACR Virtual Annual Meeting 2021 for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers

10 Mar 2021 16:35:00 By Nasdaq GlobeNewswire

Kronos Bio Announces Positive End-of-Phase 2 Meeting with FDA for Entospletinib in Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia (AML)

04 Mar 2021 07:00:01 By Nasdaq GlobeNewswire

Kronos Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers

25 Feb 2021 08:00:01 By Nasdaq GlobeNewswire

Kronos Bio Appoints Marianne De Backer, Ph.D., to Board of Directors

26 Jan 2021 08:00:02 By Nasdaq GlobeNewswire